Shared on04 Sep 25
Johnson & Johnson’s unchanged analyst price target reflects balanced sentiment, with bulls encouraged by Q2 earnings strength, improved guidance, and ongoing growth expectations, while bears flag regulatory and clinical trial risks, resulting in fair value holding steady at $177.47. Analyst Commentary Bullish analysts raised price targets following Johnson & Johnson’s Q2 earnings beat, with expectations for continued top- and bottom-line growth into 2026 and potential to exceed guidance for Innovative Medicine sales CAGR.
Shared on23 Apr 25Fair value Decreased 0.65%
AnalystConsensusTarget has decreased shares outstanding growth rate from 0.0% to -0.0%.
Shared on17 Apr 25Fair value Increased 0.88%
AnalystConsensusTarget has increased revenue growth from 3.3% to 3.6%.
Shared on09 Apr 25Fair value Decreased 0.80%
AnalystConsensusTarget has increased revenue growth from 2.9% to 3.3%, increased profit margin from 21.0% to 23.3% and increased shares outstanding growth rate from 0.0% to 0.0%.
Shared on02 Apr 25Fair value Increased 0.64%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Increased 0.089%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on11 Mar 25Fair value Increased 2.88%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.